Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
On March 27, 2026, BTIG maintained its Buy rating on Humacyte but cut its price target to $3 from $6 after the company reported fourth-quarter and full-year 2025 results earlier the same day. Humacyte reported $0.5 million in fourth-quarter revenue and $2.0 million in full-year revenue, while BTIG said the quarterly figure missed its $1.3 million estimate. The analyst note also said the company posted a loss per share of $0.13, versus consensus expectations for a $0.12 loss. Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity BTIG said the trauma launch for Symvess remains choppy on a quarter-to-quarter basis. The firm noted that Humacyte sold about 25 units in the fourth quarter, down from about 29 in the third quarter of 2025, while the price per unit declined to roughly $17,000 from about $24,500. BTIG also flagged elevated operating expenses and said cash remains a critical focus. Even so, BTIG pointed to some commercial progress, wi
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte (HUMA) had its "sell (e+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Humacyte (HUMA) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=HUMA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "strMarketBeat
- Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? [TheStreet.com]TheStreet.com
- Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR Newswire
- Humacyte (HUMA) had its price target lowered by Barclays PLC from $3.50 to $1.50. They now have an "overweight" rating on the stock.MarketBeat
HUMA
Earnings
- 3/27/26 - In-Line
HUMA
Sec Filings
- 3/27/26 - Form 10-K
- 3/24/26 - Form SCHEDULE
- 3/19/26 - Form 8-K
- HUMA's page on the SEC website